A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients

被引：6

作者：

Kida, Daihei ^{[1
]}

Takahashi, Nobunori ^{[2
]}

Kaneko, Atsushi ^{[1
]}

Hirano, Yuji ^{[3
]}

Fujibayashi, Takayoshi ^{[4
]}

Kanayama, Yasuhide ^{[5
]}

Hanabayashi, Masahiro ^{[6
]}

Yabe, Yuichiro ^{[7
]}

Takagi, Hideki ^{[8
]}

Oguchi, Takeshi ^{[9
]}

Kato, Takefumi ^{[10
]}

Funahashi, Koji ^{[11
]}

Matsumoto, Takuya ^{[12
]}

Ando, Masahiko ^{[13
]}

Kuwatsuka, Yachiyo ^{[13
]}

Tanaka, Eiichi ^{[14
]}

Yasuoka, Hidekata ^{[15
]}

Kaneko, Yuko ^{[16
]}

Hirata, Shintaro ^{[17
]}

Murakami, Kosaku ^{[18
]}

Sobue, Yasumori ^{[2
]}

Nishiume, Tsuyoshi ^{[2
]}

Suzuki, Mochihito ^{[2
]}

Yokota, Yutaka ^{[2
]}

Terabe, Kenya ^{[2
]}

Asai, Shuji ^{[2
]}

Ishiguro, Naoki ^{[2
]}

Kojima, Toshihisa ^{[2
]}

机构：

[1] Nagoya Med Ctr, Dept Orthoped Surg & Rheumatol, Naka Ku, 4-1-1 Sanno Maru, Nagoya, Aichi, Japan

[2] Nagoya Univ, Nagoya Univ Hosp, Dept Orthoped Surg & Rheumatol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan

[3] Toyohashi Municipal Hosp, Dept Rheumatol, 50 Hakken Nishi,Aotake Cho, Toyohashi, Aichi, Japan

[4] Konan Kosei Hosp, Dept Orthoped Surg, 137 Oomatsubara, Konan, Aichi, Japan

[5] Toyota Kosei Hosp, Dept Orthoped Surg, 500-1 Ibohara,Josui Cho, Toyota, Aichi, Japan

[6] Ichinomiya Municipal Hosp, Dept Orthoped Surg, 2-2-22 Bunkyo, Ichinomiya, Aichi, Japan

[7] Tokyo Shinjuku Med Ctr, Dept Rheumatol, Shinjuku Ku, 5-1 Tsukudo Cho, Tokyo, Japan

[8] Nagoya Cent Hosp, Dept Orthoped Surg, Nakamura Ku, 3-7-7 Taiko, Nagoya, Aichi, Japan

[9] Anjo Kosei Hosp, Dept Orthoped Surg, 28 Higashihirokute, Anjo, Aichi, Japan

[10] Kato Orthoped Clin, 8-4 Minami Myoudaiji Cho, Okazaki, Aichi, Japan

[11] Kariya Toyota Gen Hosp, Dept Orthoped Surg, 5-15 Sumiyoshi Cho, Kariya, Aichi, Japan

[12] Shizuoka Kosei Hosp, Dept Orthoped Surg, Aoi Ku, 23 Kitaban Cho, Shizuoka, Japan

[13] Nagoya Univ Hosp, Dept Adv Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan

[14] Tokyo Womens Med Univ, Sch Med, Dept Rheumatol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo, Japan

[15] Fujita Hlth Univ, Dept Internal Med, Div Rheumatol, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan

[16] Keio Univ Hosp, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo, Japan

[17] Hiroshima Univ Hosp, Dept Clin Immunol & Rheumatol, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan

[18] Kyoto Univ, Dept Rheumatol & Clin Immunol, Grad Sch Med, Sakyo Ku, 54 Kawaharacho, Kyoto, Japan

来源：

SCIENTIFIC REPORTS | 2020年 / 10卷 / 01期

关键词：

HEALTH-ASSESSMENT QUESTIONNAIRE; CONCOMITANT METHOTREXATE; SUBCUTANEOUS ABATACEPT; INADEQUATE RESPONSE; EFFICACY; SAFETY; PROGRESSION; POSITIVITY; ADALIMUMAB; REGISTRY;

D O I：

10.1038/s41598-020-76842-4

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N=107) and ACPA-positive (N=446) groups. 'ACPA positive' was defined as >= 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI <= 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan-Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (Delta mTSS <= 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.

引用

页数：9

共 50 条

[11] PREVALENCE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN WEST OF IRAN
Shakiba, Y.
Kiani, A.
Shakiba, N.
Moghimi, N.
Rezaeipour, M.
Izadi, B.
Salehi, S.
INFLAMMATION RESEARCH, 2011, 60 : 187 - 188
[12] CORRELATION BETWEEN ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY AND VARIOUS BACKGROUND FACTORS OF PATIENTS WITH RHEUMATOID ARTHRITIS
Sato, M.
Takemura, M.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 990 - 990
[13] Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis
Hwang, Sang Mee
Kim, Jeong-Ok
Yoo, Young-Mi
Shin, Sue
Kim, Jin Q.
Park, Myoung Hee
Song, Eun Young
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (02) : 225 - 230
[14] Is anti-cyclic citrullinated peptide antibody determination useful in synovial fluid analysis of patients with rheumatoid arthritis?
Scrivo, R.
Alessandri, C.
Riccieri, V.
Celestino, D.
Spadaro, A.
Valesini, G.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 300 - 301
[15] The role of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody in Diagnosis of Rheumatoid Arthritis
Mobini, M.
Kashi, Z.
Mahdavi, M. R.
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2010, 12 (02) : 100 - 103
[16] Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis
Wahab, Asrul Abdul
Mohammad, Marlyn
Rahman, M. M.
Said, Mohd. Shahrir Mohamed
PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2013, 29 (03) : 773 - 777
[17] Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis
Spadaro, A
Riccieri, V
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1241 - 1242
[18] Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and comorbidity
Stamenkovic, Doris
Stiglic-Rogoznica, Nives
Stiglic, Mirna
Avancini-Dobrovic, Viviana
Grubisic-Karavanic, Vlasta
Frlan-Vrgoe, Ljubinka
Radovic, Endi
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (05) : 706 - 707
[19] Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: Relation with disease aggressiveness
Del Val Del Amno, N.
Bosch, R. Ibanez
Manteca, C. Fito
Polo, R. Gutierrez
Cortina, E. Loza
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (03) : 281 - 286
[20] Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis
van Oosterhout, M.
Bajema, I.
Levarht, E. W. N.
Toes, R. E. M.
Huizinga, T. W. J.
van Laar, J. M.
ARTHRITIS AND RHEUMATISM, 2008, 58 (01): : 53 - 60

← 1 2 3 4 5 →